WGS News

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

WGS

(NASDAQ:WGS) NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially...

August 31, 2025Lawsuits
Read more →

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

WGS

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially...

August 26, 2025Lawsuits
Read more →

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

WGS

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially...

August 18, 2025Lawsuits
Read more →

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

WGS

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially...

August 13, 2025Lawsuits
Read more →

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

WGS

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading...

August 8, 2025Lawsuits
Read more →

GeneDx to Participate in Upcoming Investor Conferences

WGS

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.

August 6, 2025Investor
Read more →

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

WGS

NEW YORK, June 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially...

GENEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

WGS

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) on behalf of GeneDx stockholders. Our investigation concerns whether GeneDx has violated the federal securities laws and/or engaged in other unlawful business practices.

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGS

WGS

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

WGS

LOS ANGELES--(BUSINESS WIRE)--WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

Jefferies Upgrades GeneDx Holdings to Buy, Announces $80 Price Target

WGS

May 9, 2025
Read more →

TD Securities Maintains Buy on GeneDx Holdings, Lowers Price Target to $110

WGS

May 1, 2025
Read more →

Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Lowers Price Target to $78

WGS

May 1, 2025
Read more →

GeneDx Holdings Raises FY2025 Sales Guidance from $350.00M-$360.00M to $360.00M-$375.00M vs $425.02M Est

WGS

April 30, 2025
Read more →

GeneDx Hldgs Q1 Adj. EPS $0.27 Beats $0.16 Estimate, Sales $87.11M Beat $85.13M Estimate

WGS

April 30, 2025
Read more →

GeneDx Eyes Global Genomic Leadership With Fabric Genomics Buyout For Up To $51 Million

WGS

GeneDx (NASDAQ: WSG) to acquire Fabric Genomics, pioneer in AI-powered genomic interpretation, for up to $51 million. Expanding global reach and improving precision diagnostics.

April 16, 2025
Read more →

GeneDx Announced Its Plans To Acquire Fabric Genomics, A Pioneer In Ai-powered Genomic Interpretation For Total Consideration Potentially Up To An Aggregate Of $51M Upon Achievement Of Certain Milestones

WGS

April 16, 2025
Read more →

GeneDx Expands Commercial Expansion Into Inborn Errors Of Immunity

WGS

April 3, 2025
Read more →

GeneDx Announces Indication Expansion To Include Genetic Testing For Cerebral Palsy, Highlighting Focus On Pediatric Rare Disease Patients

WGS

March 4, 2025
Read more →

Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $80

WGS

February 19, 2025
Read more →

GeneDx Expects 2025 Revenues Of $350M-$360M Versus Consensus Of $338.782M

WGS

February 18, 2025
Read more →

GeneDx Hldgs Q4 Sales $95.64M Beat $82.23M Estimate, Adjusted Net Income Of $16.8M

WGS

February 18, 2025
Read more →

GeneDx Announces UltraRapid Whole Genome Sequencing

WGS

February 13, 2025
Read more →

GeneDx Preliminary FY24 Revenue To Exceed $299M With Q4 Revenue At Least $92M; FY Adjusted Gross Margin Projected At 64% And Q4 At 68%

WGS

January 13, 2025
Read more →